Infliximab and serious hematologic events.
Phelan
Cynthia
C
Department of Family Medicine, University of Ottawa.
Wooltorton
Eric
E
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy; D001774:Blood Chemical Analysis; D002170:Canada; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D000069285:Infliximab; D008297:Male; D008991:Monitoring, Physiologic; D018570:Risk Assessment; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab